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Background: A major hepatic resection for malignancies requires an adequate post-operative liver
reserve. Portal vein embolization (PVE) with intra-arterial therapy (IAT) may increase future liver remnant
(FLR) hypertrophy. As such, the feasibility, safety and efficacy of IAT+PVE were investigated.
Methods: Between 2000 to 2011, 86 patients with malignancy of the liver were identified from a
multi-institutional database. Twenty-nine patients underwent sequential IAT+PVE, 25 had PVE alone and
32 had IAT alone. Clinicopathological data were evaluated.
Results: Most patients had hepatocellular carcinoma (HCC) (65.1%) and 31.4% had secondary meta-
static disease. A complete or partial response using European Association for the Study of the Liver
(EASLD) criteria was seen in 48.3% of patients undergoing IAT+PVE vs. 56.6% among patients under-
going IAT (P = 0.601). The median increase in percentage FLR volume was comparable in IAT+PVE (7.4%)
vs. PVE only (7.9%) (P = 0.203). There were no IAT+PVE-associated deaths and only one complication.
Among patients treated with IAT+PVE (n = 29), 27 underwent a subsequent hepatic resection. Peri-
operative morbidity and mortality was 29.6% and 7.4%, respectively. Among the patients with HCC who
underwent curative intent surgery after IAT+PVE, the median survival was 59.0 months.
Conclusions: Sequential IAT and PVE are feasible and safe. Utilization of IAT+PVE before a resection
can lead to long-term survival and should be considered in the treatment of patients with advanced
hepatic malignancies.
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Introduction
A major hepatic resection is the only curative option for many
patients with advanced malignancies of the liver. In recent decades,
improvements in surgical technique, increased understanding of
hepatic anatomy and advances in peri-operative care have resulted
in improvements in peri-operative mortality associated with a
liver resection. Mortality is now reported to be less than 5% at
most high-volume centres.1–5 However, post-operative liver failure
remains a serious concern associated with high mortality.6 A
number of studies have identified the risk factors associated with
post-operative liver failure including cirrhosis, chemotherapy
induced steatohepatitis, sepsis and cholestasis.6,7 Most efforts to
reduce the risk of liver failure after resection have focused on
insuring an adequate post-operative hepatic reserve.4,6–8
Characterization of an adequate hepatic reserve has resulted in
the development of scoring systems and biochemical tests.9,10
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However, in most centres pre-operative measurement of the
future liver remnant (FLR) is utilized to ensure that an adequate
minimal functional liver volume will be left after resection to
avoid liver insufficiency. In general, patients with normal under-
lying hepatic parenchyma require an FLR of 20% to 30%, whereas
patients with underlying liver disease may require an FLR of 30%
to 50%.11 Pre-operative portal vein embolization (PVE) has been
utilized as a strategy to induce hypertrophy of the FLR to mitigate
the risk of liver failure among patients undergoing a major hepatic
resection. However, there have been some concerns over tumour
progression after portal vein occlusion. Several previous studies
have demonstrated either primary or metastatic tumour progres-
sion after pre-operative PVE.12–15 Preclinical evidence in mouse
models has also suggested that portal vein occlusion may increase
the growth rate of liver metastasis through growth factor secre-
tion.16 Other studies have suggested that PVE may be associated
with tumour progression through various potential routes includ-
ing a combination of growth factor secretion and increased
hepatic artery flow.17
Because of the risk of tumour progression and the desire to
treat the intrahepatic disease around the time of PVE, there has
been interest in combining PVE with intra-arterial therapy (IAT).
Sequential IAT and PVE may allow for the treatment of intrahe-
patic disease, while also increasing the hypertrophy of the FLR
owing to occlusion of both the portal and arterial flow to the
tumour-bearing liver. However, combined IAT and PVE may also
result in more morbidity as a result of double occlusion of hepatic
vascular in-flow. Data on sequential IAT and PVE prior to major
hepatic resection remain poorly defined. Most reports on the
topic have been single institution series and therefore may have
limited generalizability.18–20 The current series utilized an interna-
tional multi-centre database derived from six major hepatobiliary
centres. The short- and long-term outcomes of patients who were
managed with sequential IAT and PVE prior to hepatic resection
were examined. Specifically, the aim was to determine the feasi-
bility, safety and efficacy of combined sequential IAT and PVE.
Methods
Patients and data collection
Utilizing an international multi-institutional database, 86 patients
with an advanced malignancy of the liver diagnosed between
January 2000 and June 2011 were identified from one of six insti-
tutions (Johns Hopkins University School of Medicine, Baltimore,
MD, USA; Ohio State University, Columbus, Ohio, USA; Univer-
sity of Calgary Hospital, Calgary, Canada; Curry Cabral Hospital,
Lisbon, Portugal; Eastern Hepatobiliary Surgery Hospital, Shang-
hai, China; and Ospedale Mauriziano Umberto I, Turin, Italy).
The Institutional Review Boards of each respective institution
approved the study. The study cohort consisted of 29 patients who
had undergone a prospectively planned sequential IAT+PVE,
compared with patients who had undergone either PVE (n = 25)
or IAT (n = 32) alone.
Standard demographical and clinicopathological data were col-
lected including patient and primary tumour characteristics. Spe-
cifically, as previously described,21 data collected included patient
demographics; primary tumour size, number; serum laboratory
exams [e.g. international normalized ratio (INR), bilirubin, crea-
tinine etc.]; and model of end-stage liver disease (MELD) score.
Detailed data on imaging characteristics were also collected. Com-
plete response (CR), partial response (PR), stable disease (SD) and
progressive disease (PD) were assessed using standard European
Association for the Study of the Liver (EASL) criteria,22 as previ-
ously described.23 For those patients who underwent a resection, a
pathological response was also assessed according to established
criteria.24 Data on the type of IAT and PVE treatment, as well as
peri-procedural and long-term outcomes were also collected. IAT
was performed using conventional trans-arterial chemoemboliza-
tion (cTACE) with either cisplatin+doxorubicin+mitomycin
C or doxorubicin drug-eluting beads (DEB). PVE was performed
using either cyanoacrylate, microspheres or coils as described
previously.25–27 In general, the doses of chemotherapy for conven-
tional TACE were 100 mg of cisplatin, 50 mg of doxorubicin and
10 mg of mitomycin C mixed with lipiodol 1–2 to 1 depending on
arterial flow. The volume used was usually 10 cc of chemo + 5–15
cc of lipiodol. The size of the microspheres used to embolize as
part of conventional TACE was 100 to 300 microns. The size of the
DEB-TACE particles was 100 to 300 microns loaded with 1 vial or
50 mg of doxorubicin. In general, 1 or 2 vials were used per case.
For PVE, the particles were usually 100–500 microns, whereas for
the N-Butyl Cyanoacrylate or glue typically two tubes or 2 ml of
total mixed with lipiodol at four times the volume of glue, there-
fore approximately 8 ml was used.
Cross-sectional volumetry was performed after PVE to assess
contralateral liver hypertrophy.28,29 Survival status was determined
using both hospital records as well as the Social Security Death
Index.
Data analysis
Summary statistics were obtained using established methods
and presented as percentages or median values. The chi-square test
was used to compare categorical data, whereas the Mann-Whitney
U-test was used for continuous data. Factors including procedure-
related complications, change in FLR, tumour response on
imaging and pathology, as well as overall survival were compared
among patients undergoing sequential IAT+PVE versus either IAT
or PVE alone. Survival times were estimated using the Kaplan–
Meier method and differences were examined using the log-rank
test. A P-value of less than 0.05 was considered significant. All tests
were performed using the SPSS version 18.0 (IBM Corporation,
Armonk, NY, USA).
Results
Patient characteristics and demographics
The patient and tumour characteristics of the 86 patients who
were diagnosed with a primary or secondary hepatic tumour and
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who were included in the current study are detailed in Table 1.
Fifty-six patients had a primary hepatic cancer and 27 had sec-
ondary metastatic disease. Overall, 59 patients had a solitary liver
lesion and 21 had bilobar hepatic metastasis. The median size of
the largest lesion was 6.2 cm (range, 1.5–15.0 cm). Ten patients
had concurrent extrahepatic metastatic disease.
Although the distributions of certain factors (e.g. age, gender,
INR, creatinine and the presence of extra-hepatic disease) were
similar among the three study groups, univariate analyses revealed
several differences (Table 1). While most patients who underwent
sequential IAT+PVE (n = 24) and those who underwent IAT alone
(n = 27) had HCC, patients who underwent PVE alone more often
had colorectal liver metastasis as a diagnosis (n = 16) (P < 0.001).
Patients who underwent IAT+PVE had the largest burden of intra-
hepatic disease. Specifically, the median size of the largest intrahe-
patic lesion was 10.2 cm among patients treated with IAT+PVE vs.
6.0 cm and 5.5 cm, respectively, for patients undergoing IAT or
PVE alone (P = 0.006). There was also a corresponding difference
in the extent of hepatic involvement (>50% intrahepatic tumour
burden: IAT+PVE, 53.9% vs. IAT alone, 28.1% vs. PVE alone,
29.1%; P = 0.032).
IAT and PVE procedural details and
associated morbidity
Details regarding the IAT and PVE procedures are outlined in
Table 2. Overall, among patients undergoing IAT, patients were
treated with either cTACE with cisplatin+doxorubicin+mitomycin
C (n = 29) or DEB (n = 32). The median number of IAT treatments
was 1 (range, 1 to 4). All patients who were treated with sequential
IAT+PVE (n = 29) had IAT therapy as the initial liver-directed
therapy. Compared with patients who underwent IAT alone
(n = 10), patients who underwent sequential IAT+PVE (n = 19)
were more commonly treated with doxorubicin DEB (P = 0.010)
(Table 2). Overall, repeat IAT treatment was performed among
44.8% of IAT+PVE patients vs. 71.0% of the IAT patients. Repeat
IAT therapy most often consisted of DEB (84.6%) among IAT+PVE
Table 1 Baseline characteristics of patients according to treatment received
IAT PVE IAT & PVE P-value
(n = 32) (n = 25) (n = 29)
Age at diagnosis (years); median (range) 61.1 (13.4–74.0) 62.4 (42.4–71.3)– 60.1 (48.2–69.8) 0.316
Male gender; n 22 17 24 0.300
Race
White; n 19 23 23 <0.001
Black; n 13 1 1
Other; n 0 1 5
Cirrhotic liver; n 22 1 11 <0.001
Chemistries
Serum bilirubin (mg/dl); median (range) 1.0 (0.2–3.8) 0.7 (0.3–4.3) 0.9 (0.3–1.7) 0.078
INR; median (range) 1.1 (1.1–1.4) 1.0 (0.9–1.4) 1.1 (1.0–1.2) 0.141
Serum creatinine (mg/dl); median (range) 1.0 (0.4–1.4) 0.9 (0.7–1.2) 0.9 (0.6–1.2) 0.481
Tumour histology
HCC; n 27 5 24 <0.001
CRLM; n 2 16 1
Neuroendocrine; n 3 2 3
Cholangiocarcinoma; n 0 2 1
Tumour size (cm); median (range) 6.0 (1.5–9.4) 5.5 (1.8–12.1) 10.2 (2.9–15.0) 0.006
Lymph node metastatsis; n 4 10 0 <0.001
Extrahepatic disease; n 4 3 5 0.851
Estimated hepatic involvementa
0–25%; n 13 6 5 0.032
26–50%; n 10 11 7
51–75%; n 9 3 14
>75%; n 0 1 (4.8) 0
MELD score; median (range) 8.4 (4.4–15) 7.6 (2.5–11) 7.6 (3.0–8.2) 0.043
aData were missing for seven patients.
IAT, intra-arterial therapy; PVE, portal vein embolization; CRLM, colorectal liver metastatsis; HCC, hepatocellular carcinoma, INR, international
normalized ratio; MELD, model for end-stage liver disease.
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patients, whereas 18 of the 22 IAT-only patients who underwent a
repeat IAT received cTACE (P < 0.001).
Among the 54 patients who underwent PVE, 46 patients had
the right portal vein embolized (IAT+PVE, 89.7% vs. PVE alone,
80.0%) (P = 0.351). Six patients underwent PVE of the right
hemi-liver with concurrent embolization of segment 4 (IAT+PVE,
10.3% vs. PVE alone, 12.0%). While most PVE-alone patients
were treated with N-butyl cyanoacrylate (n = 18), IAT+PVE
patients were treated using several different approaches (N-butyl
cyanoacrylate in 12; microspheres in 9; and coils+polyvinyl
alcohol in 6) (P = 0.014). Of the 29 patients who underwent
sequential liver-directed therapy, the median time between
the initial IAT and subsequent PVE was 60 days (range, 28
to 102).
Table 2 Details of procedures undergone by the patients
IAT PVE IAT & PVE P-value
(n = 32) (n = 25) (n = 29)
Portal vein embolization
Vein(s) occluded
Right portal vein; n – 20 26 0.350
Left portal vein; n – 2 0
Right portal vein+left segment 4; n – 3 3
Embolization material –
N-butyl cyanoacrylate; n – 22 12 0.014
Microspheres; n – 1 9
Coils+polyvinyl alcohol; n – 2 6
Procedure-related complications; n – 3 0 0.093
Intra-arterial therapy regimen 1
Extent of tumour
Unilobar; n 20 – 18 0.941
Bilobar; n 12 – 11
Chemotherapy regimen –
Cisplatin+doxorubicin+mitomycin C; n 22 – 10 0.010
Doxorubicin DEB; n(%) 10 – 19
Procedure-related complications; n 1 – 1 0.902
Accompanied systemic chemotherapy; n 1 – 4 0.181
Intra-arterial therapy regimen 2
Patients undergoing second IAT; n 22a – 13 0.402
Chemotherapy regimen; n –
Cisplatin+doxorubicin+mitomycin C; n 18 – 2 <0.001
Doxorubicin DEB; n 4 – 11
Procedure-related complications; n 0 – 1
Accompanied systemic chemotherapy; n 0 – 3 0.040
Surgical resection
Patients undergoing surgery; n 0 19 27 <0.001
Type of operation
Hemi-hepatectomy – 7 15 0.171
Extended resection – 12 12
Margin status –
R0 – 19 26 0.594
R1 – 0 1
Procedure-related complications; n – 6 8 0.891
Operative mortality, n – 1 2 0.190
aFrom a total of 31 patients. One patient had complications arising from the first IAT.
IAT, intra-arterial therapy; PVE, portal vein embolization; DEB, drug-eluting beads.
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Morbidity and mortality after IAT and PVE were uncommon.
Five patients experienced a peri-procedural complication; there
was only one death. The death occurred in a patient who had
undergone IAT alone. This patient was 71 years old and had HCC
with a pre-IAT bilirubin of 3.8 and MELD score of 15. After IAT
therapy with cTACE, the patient developed worsening liver insuf-
ficiency and died post-procedure day 26. Among those patients
who underwent PVE alone, there were no peri-procedural deaths
but there were three patients who had complications. Complica-
tions included a hepatic abscess, haemolytic anaemia and sepsis.
Similarly, there were no procedural-related deaths after sequential
IAT+PVE. One patient did experience a complication of a hepatic
abscess related to IAT therapy, but this resolved with conservative
management and antibiotics.
IAT and PVE: the impact on FLR, tumour response
and surgical therapy
The efficacy of IAT was assessed comparing patients who under-
went sequential IAT+PVE vs. patients who underwent IAT only
(Table 3). Targeted lesions were evaluated for treatment response
by assessing tumour necrosis on cross-sectional imaging using
established EASLD criteria.22,23 Among patients treated with IAT
alone, 16 and 1 patients had a PR or CR, respectively. Thirteen
patients had SD. Among the patients who underwent sequential
IAT+PVE, 12 and 2 patients, respectively, had a PR or CR whereas
15 patients had SD on cross-sectional imaging using EASLD
criteria. No patient in either group had PD. Overall there was no
difference in the response rate (PR+CR) using EASLD criteria
when comparing IAT alone (56.6%) vs. sequential IAT+PVE
(48.3%) (P = 0.601).
The degree of FLR hypertrophy was also assessed comparing
patients who underwent sequential IAT+PVE vs. patients who
underwent PVE alone. The median time to FLR assessment
from time of PVE was 47.8 days (range, 15 to 95). The percent
increase in FLR was comparable after PVE alone vs. sequential
IAT+PVE (PVE alone, 7.9% vs. sequential IAT+PVE, 7.4%;
P = 0.203) (Fig. 1).
Among patients who underwent PVE alone (n = 25), 19 under-
went a resection. In contrast among patients treated with IAT+PVE
(n = 29), 27 patients underwent subsequent hepatic resection.
In this latter group, a hepatic resection consisted of hemi-
hepatectomy (n = 15) or extended hepatic resection (n = 12). The
surgical margin was microscopically negative in the majority of
patients (n = 26). On final pathological analysis, greater than 50%
tumour necrosis was noted among most patients (n = 11), with
many patients having 75% or more tumour necrosis (n = 9)
(Fig. 2).
Morbidity and mortality after a hepatic resection among those
patients who had pre-operative sequential IAT+PVE was noted in
8 and 2 patients, respectively. The two post-operative deaths were
related to liver insufficiency/failure in cirrhotic patients who had
pre-operative FLR volumes of 598 ml (27%) and 530 ml (34%).
Table 3 Response to procedures by type of procedure undergone by patients
IAT PVE IAT & PVE P-value
(n = 32) (n = 25) (n = 29)
Percent increase in FLR volume; median (range) 0.94 (0–1.4) 7.9 (4.1–14.7) 7.4 (2.2–11.6) 0.017
EASL responsea
Complete response, n 1 – 2 0.601
Partial response, n 16 – 12
Stable disease, n 13 – 15
Pathological response (% necrosis)b
0–25; n – 7 4 0.843
26–50%; n – 14 4
51–75%; n – 0 2
75–100%; n – 1 9
Recurrence; n N/A 7 9 0.809
Condition at final follow-up
Alive without evidence of disease; n 0 8 18 <0.001
Alive with disease; n 25 13 5
Died of disease; n 3 3 5
Died of other causes; n 4 1 1
aOne patient in the IAT group did not return for response evaluation. Data missing for another patient. Total in group is 30 patients.
bNo pathology specimens were available for patients undergoing IAT as none underwent surgery. Data were available for a limited number of patients
in the other two groups.
IAT, intra-arterial therapy; PVE, portal vein embolization; FLR, future liver remnant; EASL, European Association for the Study of the Liver.
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Among all patients who underwent resection after sequential
IAT+PVE, the median and 3-year survival was 58 months and
87.4%, respectively. Among patients with HCC (n = 24) who
underwent surgery after IAT+PVE, the median survival was 59.0
months and 1-, and 3-year survival was 85.7% and 66.7%, respec-
tively. At a median follow-up of 16.7 months, 18 patients with
HCC who underwent resection after IAT+PVE were alive and
disease-free.
Discussion
Surgery is being increasingly considered for patients with a large
intrahepatic burden of disease that requires a major hepatic resec-
tion. Determination of resectability is based on preserving blood
flow and biliary drainage to two contiguous liver segments while
also preserving enough remnant liver to avoid liver failure.30,31 To
mitigate the risk of post-operative liver insufficiency, PVE has
been employed to increase the FLR. However, there is some
concern that while PVE may induce hypertrophy of the FLR, there
may also be concomitant tumour growth during this period of
time.12–17 Some investigators have suggested that IAT combined
with PVE may have an increased therapeutic effect on the intra-
hepatic tumour owing to obstruction of the tumour-feeding
vessels and suppression of intrahepatic spread by portal vein
invasion.25,32–34 However, double occlusion of the blood supply
to the tumour-bearing liver may result in an increased risk of
ischaemia, liver damage and complications. Less than a handful of
studies have reported on the use of sequential IAT+PVE for
patients with advanced liver malignancies.18–20 Two of the three
previous reports included fewer than 20 patients19,20 and all pre-
vious studies were single institution experiences.18–20 The current
study is important because it examined an international experi-
ence with sequential IAT+PVE. This enabled a wide range of
IAT+PVE techniques in a more ‘real-world’ setting to be reported,
making these findings more broadly applicable. In the present
study, IAT+PVE was noted to be feasible and safe, with no related
deaths and only one patient complication. Sequential IAT+PVE
did not result in additional FLR hypertrophy, but a subset of
patients with extensive intrahepatic disease who did undergo a
resection after IAT+PVE were noted to have significant tumour
necrosis on final pathology and experienced long-term survival.
One of the main concerns with sequential IAT+PVE regards the
double occlusion of vascular inflow to the tumour-bearing hemi-
liver. Parenchymal damage can occur after IAT alone as evidenced
by elevation in liver enzymes including aspartate aminotrans-
ferase (AST) and alanine aminotransferase (ALT).18,35,36 Most
often these elevations are transient; however, the concern with
IAT+PVE is that any ischaemic effect may be more severe and long
standing. In the study by Yoo et al., the authors reported that
nearly all patients treated with IAT+PVE had only a mild elevation
in AST and ALT within 3 days after IAT that quickly normalized
and no patient had abnormal elevation in enzymes after subse-
quent PVE.18 In this study, only one patient who underwent
IAT+PVE had markedly and persistently elevated liver enzymes
that that did not normalize 3 months after PVE. Of note, Yoo
et al. noted that no patient experienced a significant complication
after IAT+PVE. In the present study, we similarly found that
IAT+PVE was well tolerated with no peri-procedural deaths and
only one serious complication. While liver function enzymes after
IAT+PVE were not formally assessed, the one specific complica-
tion – hepatic abscess – did appear to be related to relative
ischaemia and super-infection of the treated hemi-liver. In aggre-
gate, data from the current study as well as data published by
others,18–20 demonstrate that pre-operative sequential IAT+PVE
can be performed safely.
In the present study, the median increase in percentage FLR
volume was not different in the IAT+PVE group compared with
the PVE only group. In fact, the percent increase in FLR was
virtually identical after sequential IAT+PVE (7.4%) vs. PVE alone
(7.9%) (Fig. 1). In contrast, Yoo et al. had reported that sequential
IAT+PVE was an effective method to increase the rate of
FLR hypertrophy and was associated with a significantly higher
percent change in FLR.18 Specifically, in the study by Yoo et al.,
the mean increase in percentage FLR volume was 7.3% in the
IAT+PVE group compared with 5.8% in the PVE-only group.18
The reasons for the difference in the present findings compared
with the study by Yoo et al. are probably multi-factorial. Different
techniques were employed for the IAT and PVE procedures in
each study. Specifically, gelatin sponge embolization was the main
method of PVE in the Yoo et al. study, whereas a variety of
Figure 1 The percent increase in future liver remnant (FLR) was
comparable after portal vein embolization (PVE) alone vs. sequential
intra-arterial therapy (IAT)+PVE (PVE alone, 7.9% vs. sequential
IAT+PVE, 7.4%; P = 0.203)
528 HPB
HPB 2012, 14, 523–531 © 2012 International Hepato-Pancreato-Biliary Association
approaches were used in the present study (Table 2). In addition,
Yoo and colleagues routinely performed IAT using a cisplatin-
lipiodol emulsion, which tends to be more ‘embolic’ than the DEB
IAT therapy that was delivered to half (52.5%) of the patients in
the present study. These differences may explain, in part, the lower
than expected change in FLR in the ‘control’ PVE alone group of
only 5.8% in the Yoo et al. study.18 It is interesting to note that the
change in FLR for the IAT+PVE (7.4%) and PVE only (7.9%)
groups in the present study were nearly identical to the IAT+PVE
group (7.3%) in the Yoo et al. study. Furthermore, the reported
FLR changes in the Yoo et al. study had wide standard errors
that overlapped considerably between the two groups (IAT+PVE:
7.3% 3.6% vs. PVE only group: 5.8% 4.5%) – again calling
into question any significant difference between the groups. In
turn, taken together, IAT+PVE does not appear to be associated
with a marked difference in FLR hypertrophy compared with PVE
alone.
Rather than reducing the tumour size, the goal of IAT treatment
is to induce tumour necrosis. IAT alone has been associated with
a mean tumour necrosis of 50% to 60% and the effect of IAT has
been shown to be related to the size of the targeted lesion.37 In the
present study, the median tumour size among patients undergo-
ing IAT+PVE was almost 10 cm and over one-half of patients had
greater than 50% estimated tumour involvement of the liver. In
spite of this high burden of disease, IAT+PVE was associated with
a good therapeutic response. Specifically, 48.3% of patients had
either a partial or complete response based on EASLD criteria on
cross-sectional imaging. In addition, among those patients who
underwent a resection, 47.4% of patients were noted to have sig-
nificant tumour necrosis of 75% to 100%. Ogata et al. had simi-
larly noted a higher response for IAT among patient treated with
combined IAT+PVE.19 IAT+PVE resulted not only in high patho-
logical response rates, but also long-term survival in a subset of
patients. Among patients who underwent a resection after sequen-
tial IAT+PVE the median survival was 58 months. In examining
only HCC patients treated with IAT+PVE and resection, the
median survival was 59.0 months and, perhaps more interestingly,
three-quarters of these patients were alive and disease free. Other
investigators have suggested that combined IAT+PVE may
decrease the rate of intrahepatic recurrence by pre-operatively
suppressing potential intrahepatic spread via the portal vein as
well as occluding arterioportal shunts.18,32–34 Future studies will be
needed to evaluate more fully the impact of IAT+PVE on overall
and disease-free survival.
The present study has a number of limitations that need to be
considered. In spite of assembling the experience of some of the
largest hepato-biliary centres in the world, only a small number of
patients who underwent sequential IAT+PVE could be identified.
Because of the small number of patients who underwent IAT+PVE
identified for this study, there were limitations with regard to
statistical modelling and power. In addition, like all retrospective
studies, the data may be subject to selection bias. Given the relative
heterogeneity among patient and tumour characteristics, as well as
the types of therapy administered, comparisons of patients treated
with IAT+PVE vs. IAT or PVE alone may be limited. While direct
comparisons may be problematic, the present study achieved its
main objective of defining the safety and feasibility of IAT+PVE as
well as providing general information regarding the effect of
IAT+PVE on FLR and tumour necrosis.
In conclusion, sequential IAT+PVE prior to a hepatic resection
is both feasible and safe. Combined therapy did not result in
an appreciable increase in percent FLR compared with PVE
alone. However, sequential IAT and PVE was associated with a
significant tumour response both by EASLD criteria and on final
pathology among those patients who underwent a resection.
Furthermore, patients treated with IAT+PVE prior to a resection
Figure 2 Histological findings showing tumour response. Presence of extensive necrosis with no viable tumour. Note the embedded
drug-eluting beads (DEB) post-intra-arterial therapy (IAT) (arrow)
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had a median survival approaching 5 years and many were
disease-free at the time of last follow-up. As such, utilization of
IAT+PVE prior to resection should be considered with advanced
hepatic malignancies. Sequential IAT+PVE should especially be
considered in those patients with a small FLR who have a large
burden of intra-hepatic disease that would benefit from treatment
while awaiting hypertrophy. Combined IAT+PVE in this setting
may provide for hypertrophy of the FLR while also treating the




1. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O.
(2000) Seven hundred forty-seven hepatectomies in the 1990s: an update
to evaluate the actual risk of liver resection. J Am Coll Surg 191:38–46.
Epub 2000/07/18.
2. Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S et al.
(2002) Improvement in perioperative outcome after hepatic resection:
analysis of 1,803 consecutive cases over the past decade. Ann Surg
236:397–406. discussion -7. Epub 2002/10/09.
3. Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C et al. (1999)
Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths.
Ann Surg 229:322–330. Epub 1999/03/17.
4. Taketomi A, Kitagawa D, Itoh S, Harimoto N, Yamashita Y, Gion T et al.
(2007) Trends in morbidity and mortality after hepatic resection for hepa-
tocellular carcinoma: an institute's experience with 625 patients. J Am
Coll Surg 204:580–587. Epub 2007/03/27.
5. Fan ST, Lai EC, Lo CM, Ng IO, Wong J. (1995) Hospital mortality of major
hepatectomy for hepatocellular carcinoma associated with cirrhosis.
Arch Surg 130:198–203. Epub 1995/02/01.
6. Garcea G, Maddern GJ. (2009) Liver failure after major hepatic resection.
J Hepatobiliary Pancreat Surg 16:145–155. Epub 2008/12/27.
7. Khan AZ, Morris-Stiff G, Makuuchi M. (2009) Patterns of chemotherapy-
induced hepatic injury and their implications for patients undergoing liver
resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg
16:137–144. Epub 2008/12/19.
8. Tamandl D, Gruenberger B, Klinger M, Herberger B, Kaczirek K,
Fleischmann E et al. (2010) Liver resection remains a safe procedure after
neoadjuvant chemotherapy including bevacizumab: a case-controlled
study. Ann Surg 252:124–130. Epub 2010/06/22.
9. Schneider PD. (2004) Preoperative assessment of liver function. Surg Clin
North Am 84:355–373. Epub 2004/04/06.
10. Mitsumori A, Nagaya I, Kimoto S, Akaki S, Togami I, Takeda Y et al. (1998)
Preoperative evaluation of hepatic functional reserve following hepatec-
tomy by technetium-99m galactosyl human serum albumin liver scintig-
raphy and computed tomography. Eur J Nucl Med 25:1377–1382. Epub
1998/11/18.
11. Vauthey JN, Dixon E, Abdalla EK, Helton WS, Pawlik TM, Taouli B et al.
(2010) Pretreatment assessment of hepatocellular carcinoma: expert
consensus statement. HPB 12:289–299. Epub 2010/07/02.
12. Elias D, De Baere T, Roche A, Ducreux RM, Leclere J, Lasser P. (1999)
During liver regeneration following right portal embolization the growth
rate of liver metastases is more rapid than that of the liver parenchyma.
Br J Surg 86:784–788.
13. Barbaro B, Di Stasi C, Nuzzo G, Vellone M, Giuliante F, Marano P. (2003)
Preoperative right portal vein embolization in patients with metastatic
liver disease. Metastatic liver volumes after RPVE. Acta Radiol 44:98–
102. Epub 2003/03/13.
14. Kokudo N, Tada K, Seki M, Ohta H, Azekura K, Ueno M et al. (2001)
Proliferative activity of intrahepatic colorectal metastases after preopera-
tive hemihepatic portal vein embolization. Hepatology 34:267–272. Epub
2001/08/02.
15. Hayashi S, Baba Y, Ueno K, Nakajo M, Kubo F, Ueno S et al.
(2007) Acceleration of primary liver tumor growth rate in embolized
hepatic lobe after portal vein embolization. Acta Radiol 48:721–727. Epub
2007/08/31.
16. Heinrich S, Jochum W, Graf R, Clavien PA. (2006) Portal vein ligation
and partial hepatectomy differentially influence growth of intrahepatic
metastasis and liver regeneration in mice. J Hepatol 45:35–42. Epub
2006/05/16.
17. de Graaf W, van den Esschert JW, van Lienden KP, van Gulik TM. (2009)
Induction of tumor growth after preoperative portal vein embolization: is
it a real problem? Ann Surg Oncol 16:423–430. Epub 2008/12/04.
18. Yoo H, Kim JH, Ko GY, Kim KW, Gwon DI, Lee SG et al. (2011) Sequential
transcatheter arterial chemoembolization and portal vein embolization
versus portal vein embolization only before major hepatectomy for
patients with hepatocellular carcinoma. Ann Surg Oncol 18:1251–1257.
Epub 2010/11/12.
19. Ogata S, Belghiti J, Farges O, Varma D, Sibert A, Vilgrain V. (2006)
Sequential arterial and portal vein embolizations before right hepatec-
tomy in patients with cirrhosis and hepatocellular carcinoma. Br J Surg
93:1091–1098. Epub 2006/06/17.
20. Aoki T, Imamura H, Hasegawa K, Matsukura A, Sano K, Sugawara Y et al.
(2004) Sequential preoperative arterial and portal venous embolizations in
patients with hepatocellular carcinoma. Arch Surg 139:766–774. Epub
2004/07/14.
21. Demirjian A, Peng P, Geschwind JF, Cosgrove D, Schutz J, Kamel IR
et al. (2011) Infiltrating hepatocellular carcinoma: seeing the tree through
the forest. J Gastrointest Surg 15:2089–2097. Epub 2011/07/05.
22. Bruix J, Sherman M. (2005) Management of hepatocellular carcinoma.
Hepatology 42:1208–1236. Epub 2005/10/27.
23. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF.
(2009) Unresectable hepatocellular carcinoma: serial early vascular and
cellular changes after transarterial chemoembolization as detected with
MR imaging. Radiology 250:466–473. Epub 2009/02/04.
24. Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V
et al. (2007) Importance of histological tumor response assessment in
predicting the outcome in patients with colorectal liver metastases
treated with neo-adjuvant chemotherapy followed by liver surgery. Ann
Oncol 18:299–304. Epub 2006/10/25.
25. Yoo H, Ko GY, Gwon DI, Kim JH, Yoon HK, Sung KB et al. (2009)
Preoperative portal vein embolization using an amplatzer vascular plug.
Eur Radiol 19:1054–1061. Epub 2008/12/06.
26. Madoff DC, Hicks ME, Abdalla EK, Morris JS, Vauthey JN. (2003)
Portal vein embolization with polyvinyl alcohol particles and coils in
preparation for major liver resection for hepatobiliary malignancy: safety
and effectiveness–study in 26 patients. Radiology 227:251–260. Epub
2003/03/05.
27. Ko GY, Sung KB, Yoon HK, Kim JH, Weon YC, Song HY. (2003)
Preoperative portal vein embolization with a new liquid embolic agent.
Radiology 227:407–413. Epub 2003/03/15.
530 HPB
HPB 2012, 14, 523–531 © 2012 International Hepato-Pancreato-Biliary Association
28. Zacharia TT. (2006) Assessment of future remnant liver regeneration after
portal vein embolization using three-dimensional CT and MR volumetric
analyses. Australas Radiol 50:543–548. Epub 2006/11/17.
29. Kishi Y, Abdalla EK, Chun YS, Zorzi D, Madoff DC, Wallace MJ et al.
(2009) Three hundred and one consecutive extended right hepatecto-
mies: evaluation of outcome based on systematic liver volumetry. Ann
Surg 250:540–548. Epub 2009/09/05.
30. Mayo SC, Pawlik TM. (2009) Current management of colorectal hepatic
metastasis. Expert Rev Gastroenterol Hepatol 3:131–144. Epub 2009/04/
09.
31. Pawlik TM, Choti MA. (2007) Surgical therapy for colorectal metastases
to the liver. J Gastrointest Surg 11:1057–1077. Epub 2007/05/29.
32. Palavecino M, Chun YS, Madoff DC, Zorzi D, Kishi Y, Kaseb AO et al.
(2009) Major hepatic resection for hepatocellular carcinoma with or
without portal vein embolization: perioperative outcome and survival.
Surgery 145:399–405. Epub 2009/03/24.
33. Murata S, Tajima H, Nakazawa K, Onozawa S, Kumita S, Nomura K.
(2009) Initial experience of transcatheter arterial chemoembolization
during portal vein occlusion for unresectable hepatocellular carcinoma
with marked arterioportal shunts. Eur Radiol 19:2016–2023. Epub 2009/
02/25.
34. Kang BK, Kim JH, Kim KM, Ko GY, Yoon HK, Gwon DI et al. (2009)
Transcatheter arterial chemoembolization for hepatocellular carcinoma
after attempted portal vein embolization in 25 patients. AJR Am J
Roentgenol 193:W446–W451. Epub 2009/10/22.
35. Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF.
(2011) Phase II trial of sorafenib combined with concurrent transarterial
chemoembolization with drug-eluting beads for hepatocellular carci-
noma. J Clin Oncol 29:3960–3967. Epub 2011/09/14.
36. Liapi E, Geschwind JF. (2007) Transcatheter and ablative therapeutic
approaches for solid malignancies. J Clin Oncol 25:978–986. Epub 2007/
03/14.
37. Herber S, Biesterfeld S, Franz U, Schneider J, Thies J, Schuchmann M
et al. (2008) Correlation of multislice CT and histomorphology in HCC
following TACE: predictors of outcome. Cardiovasc Intervent Radiol
31:768–777. Epub 2008/01/16.
HPB 531
HPB 2012, 14, 523–531 © 2012 International Hepato-Pancreato-Biliary Association
